Indevus Pharmaceuticals has received a United States patent for it’s overactive bladder treatment, the drug Sanctura XR. Good until January 2025, this once-a-day treatment is, according to Indevus’s Website, the only approved quaternary amine compound for the treatment of overactive bladder.
This compound can relax the smooth muscle tissue in the bladder, decreasing the contractions that lead to over activity. As many spinal cord injury (SCI) patients know first hand, they are particularly prone to developing an overactive bladder due to the nerve pathways between the bladder and brain becoming interrupted.
With the use of dugs such as Sanctura XR, patients are hopefully able to avoid painful surgeries and extended recovery periods. Of course, as with all drugs, the degree of benefit depends on its interaction with each individual patient. We aren’t advocating for this particular drug, only sharing your latest options!